Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?

Abstract Background The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (I...

Full description

Bibliographic Details
Main Authors: Enrico Marinelli, Francesco Paolo Busardò, Simona Zaami
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Medical Ethics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12910-020-00562-7
id doaj-ad2bef7e9e4f45739719c28d12f03841
record_format Article
spelling doaj-ad2bef7e9e4f45739719c28d12f038412020-11-25T04:11:56ZengBMCBMC Medical Ethics1472-69392020-11-012111510.1186/s12910-020-00562-7Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?Enrico Marinelli0Francesco Paolo Busardò1Simona Zaami2Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of RomeDepartment of Excellence of Biomedical Sciences and Public Health, University Politecnica delle MarcheDepartment of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of RomeAbstract Background The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). Main text Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying “clinical soundness” as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a “moderately utilitarian” approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. Conclusions The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency.http://link.springer.com/article/10.1186/s12910-020-00562-7COVID-19EmergencyEthics
collection DOAJ
language English
format Article
sources DOAJ
author Enrico Marinelli
Francesco Paolo Busardò
Simona Zaami
spellingShingle Enrico Marinelli
Francesco Paolo Busardò
Simona Zaami
Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
BMC Medical Ethics
COVID-19
Emergency
Ethics
author_facet Enrico Marinelli
Francesco Paolo Busardò
Simona Zaami
author_sort Enrico Marinelli
title Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
title_short Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
title_full Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
title_fullStr Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
title_full_unstemmed Intensive and pharmacological care in times of COVID-19: A “special ethics” for emergency?
title_sort intensive and pharmacological care in times of covid-19: a “special ethics” for emergency?
publisher BMC
series BMC Medical Ethics
issn 1472-6939
publishDate 2020-11-01
description Abstract Background The Authors have laid out an analysis of Italian COVID-19 confirmed data and fatality rates, pointing out how a dearth of health care resources in northern regions has resulted in hard, ethically challenging decisions in terms of granting patient access to intensive care units (ICU). Main text Having to make such decisions certainly entails substantial difficulties, and that has led many health care professional to seek ethical guidance. The Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) has attempted to meet that growing need by a set of recommendations, applying “clinical soundness” as a beacon standard; that approach tends to prioritize patients with higher life expectancy, which could be characterized as a “moderately utilitarian” approach. Yet, such a selection has engendered daunting ethical quandaries. The authors believe it can only be warranted and acceptable if rooted in a transparent decision-making process and verifiable, reviewed criteria. Moreover, the authors have stressed how clinical experimentation in a pandemic setting is a subtext of great interest from an ethical perspective. In Italy, no drug therapy and trials were undertaken for COVID-19 patients for a rather long period of time. When the epidemic was already circulating, an intervention proved necessary on the system of administrative procedures, aimed at expediting the authorization and validation of protocols, then bogged down by bureaucracy. A new system has since been instituted by a government decree that was signed about one month after the first Covid-19 case was officially recorded in the country. Such a swift implementation, which took just a few weeks, is noteworthy and proves that clinical trials can be initiated in a timely fashion, even with a pandemic unfolding. The concerted, action of supportive care and RCTs is the only way to attain effective forms of treatments for COVID-19 and any other future outbreak. Conclusions The authors have arrived at the conclusion that the most effective and ethically sound response on the part of any national health care system would be to adequately reconfigure its organizational mechanisms, by making clinical trials and all related administrative procedures consistent with the current state of emergency.
topic COVID-19
Emergency
Ethics
url http://link.springer.com/article/10.1186/s12910-020-00562-7
work_keys_str_mv AT enricomarinelli intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency
AT francescopaolobusardo intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency
AT simonazaami intensiveandpharmacologicalcareintimesofcovid19aspecialethicsforemergency
_version_ 1724416397969195008